Hallucinogenic N-methylated indolealkylamines in the cerebrospinal fluid of psychiatric and control populations.
L Corbett, S T Christian, R D Morin, F Benington, J R Smythies
The British Journal of Psychiatry February 1, 1978 DOI: 10.1192/bjp.132.2.139 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Population | Patients with acute schizophrenia and surgical and neurological controls |
| Citations | 49 |
| Key findings | Some schizophrenic patients have higher levels of dimethyltryptamine and O-methylbufotenine in cerebrospinal fluid than controls, but the differences did not reach statistical significance. |
Abstract
The incidence and quantities of dimethyltryptamine and O-methylbufotenine were studied in the cerebrospinal fluid of patients suffering acute schizophrenic illnesses and in surgical and neurological control groups. Some schizophrenic patients have higher levels of both amines than do controls, though the differences in distribution did not reach statistical significance in the sample studied. The gas-chromatographic technique used is sensitive at the low picogram level.
Citations in the library
Cited by 25
- Human psychopharmacology of N,N-dimethyltryptamine Behavioural Brain Research December 1, 1995
- N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function Frontiers in Neuroscience August 6, 2018
- Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. Journal of Neural Transmission September 12, 2009
- A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955-2010. Drug Testing and Analysis 2012
- The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) Journal of Neurochemistry February 12, 2022
and 20 more in the library